We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of patency and device-related thrombus were ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...

Results of the Embolic Protection in Patients with Atrial Fibrillation (PROTECT-AF) showed that in AF patients who were candidates for warfarin therapy, device closure of the LAA using the Watchman ...

Please provide your email address to receive an email when new articles are posted on . A next-generation LAA closure device gained FDA approval to reduce risk for stroke in patients non-valvular AF.

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

(RTTNews) - Medical technology company Boston Scientific Corp. (BSX) announced Tuesday that it has received U.S. Food and Drug Administration approval for expanded labeling of WATCHMAN FLX Left Atrial ...

VIENNA, AUSTRIA — Thrombi were sometimes found on two left-atrial-appendage (LAA) occluder devices in the weeks following implantation in two large registry studies of patients with atrial ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, ...